Tag Archives: DARIC33

Will 2seventy’s Novel Pipeline Assets be Innovative Enough? 2seventy’s Research Deep Dive Investor Event Summary

On September 21 – 22, 2seventy bio (bluebird bio’s oncology business) held two Research Deep Dive sessions (Day 1 presentation / Day 2 presentation) detailing their novel pipeline assets across liquid and solid tumors. Below, Celltelligence provides insights on how 2seventy’s novel assets compare with key competitors, while discussing innovative manufacturing options for 2seventy.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.